Dyne Therapeutics Inc. (DYN) shares plummeted 5.08% during intraday trading on Tuesday, as the stock faced significant selling pressure.
The decline followed downward revisions to the company's price targets by multiple Wall Street analysts. Morgan Stanley cut its target price on Dyne Therapeutics to $47.00 from $50.00, while H.C. Wainwright lowered its target to $50 from $60, though it maintained a Buy rating on the shares.
These analyst actions, which reflect adjusted expectations for the company's future performance, contributed to negative market sentiment and drove the stock's sharp decline during the trading session.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.